Products Categories

Probiotics powder Akkermansia muciniphila(AKK)

Basic Information

Akkermansia Muciniphila was a Gram-negative, strictly anaerobic, non-motile, non-spore-forming, oval-shaped bacterium that could grow singly and in pairs.When grown on mucin medium, cells produced a capsule and were found to aggregate. Strain MucT could grow on a limited number of sugars, including N-acetylglucosamine, N-acetylgalactosamine and glucose, but only when a protein source was provided and with a lower growth rate and final density than on mucin.

product details

product description

product Specification

Items	Specification
Physical & Chemical Properties
Appearance	Light yellow to brown yellow powder
Genetic Identification	16s-rRNA method etc.
Odor	No abnormal odor
Water activity	<0.12
Moisture, %	≤ 5.0
Microbiology
Viable cell count, CFU/g	≥ 1.0*10⁶
Non LAB count, CFU/g	≤ 500
Coliform, CFU/g	≤ 10
Yeast & Mold, CFU/g	≤ 50
Escherichia coli /25g	Negative
Salmonella/25g	Negative
Staphylococcus aureus/25g	Negative
Shigella/25g	Negative
Heavy Metals
Lead (Pb) ppm	<1.0
Arsenic (As) ppm	<0.5
Cadmium (Cd) ppm	<1.0
Mercury (Hg) ppm	<0.1

Health Benefits

Akkermansia muciniphila exists in about 90% of healthy people, occupies about 1% to 3% of the fecal microbiota, colonizes the gut in the first year of life, decreases with age and deterioration of health, and is used in many countries and regions for the source of probiotics. It can degrade mucins to produce beneficial products, such as short-chain fatty acids that contribute to the growth of other bacteria and maintain healthy mucus turnover (similar to many probiotics); and also maintain microbial balance (similar to many probiotics) by competing with other mucin-degradable bacteria and inhibiting their overgrowth.

So the EU recognizes Akkermansia muciniphila as a new food, oral Akkermansia muciniphila, whether live or pasteurized, which is safe and well tolerated in overweight and obese individuals. Therefore, new food and functional food are used in many countries and regions for health management, and clinical trials also include diseases such as metabolic syndrome (such as obesity).